beta-Endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. 1985

G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani

We measured CSF and plasma contents of beta-endorphin (beta-EP), beta-lipotropin (beta-LPH), and ACTH in 24 patients with Parkinson's disease; 14 had not been treated. CSF beta-EP concentrations in untreated patients were lower than in 15 controls (p less than 0.005), but values did not differ significantly in treated and untreated patients. In untreated and treated patients, ACTH and beta-LPH CSF, and beta-EP, beta-LPH, and ACTH plasma concentrations were in the same range as controls. The Parkinson's disease-related decrease of CSF beta-EP levels further supports the concept that there is a generalized brain disorder in Parkinson's disease affecting more than dopaminergic neurons in the substantia nigra.

UI MeSH Term Description Entries
D008083 beta-Lipotropin A 90-amino acid peptide derived from post-translational processing of pro-opiomelanocortin (POMC) in the PITUITARY GLAND and the HYPOTHALAMUS. It is the C-terminal fragment of POMC with lipid-mobilizing activities, such as LIPOLYSIS and steroidogenesis. Depending on the species and the tissue sites, beta-LPH may be further processed to yield active peptides including GAMMA-LIPOTROPIN; BETA-MSH; and ENDORPHINS. Lipotropin,Adipozin,beta-LPH,beta-Lipotrophin,beta LPH,beta Lipotrophin,beta Lipotropin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D004723 Endorphins One of the three major groups of endogenous opioid peptides. They are large peptides derived from the PRO-OPIOMELANOCORTIN precursor. The known members of this group are alpha-, beta-, and gamma-endorphin. The term endorphin is also sometimes used to refer to all opioid peptides, but the narrower sense is used here; OPIOID PEPTIDES is used for the broader group. Endorphin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000324 Adrenocorticotropic Hormone An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). ACTH,Adrenocorticotropin,Corticotropin,1-39 ACTH,ACTH (1-39),Adrenocorticotrophic Hormone,Corticotrophin,Corticotrophin (1-39),Corticotropin (1-39),Hormone, Adrenocorticotrophic,Hormone, Adrenocorticotropic
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001615 beta-Endorphin A 31-amino acid peptide that is the C-terminal fragment of BETA-LIPOTROPIN. It acts on OPIOID RECEPTORS and is an analgesic. Its first four amino acids at the N-terminal are identical to the tetrapeptide sequence of METHIONINE ENKEPHALIN and LEUCINE ENKEPHALIN. Endorphin, beta,beta-Endorphin (1-31),beta Endorphin

Related Publications

G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani
September 1989, Neuroscience letters,
G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani
July 1978, Lancet (London, England),
G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani
February 1980, The Journal of clinical endocrinology and metabolism,
G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani
December 1982, Australian paediatric journal,
G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani
May 1991, Developmental medicine and child neurology,
G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani
August 1982, The Journal of clinical endocrinology and metabolism,
G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani
June 1986, Life sciences,
G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani
December 1986, Regulatory peptides,
G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani
June 1997, Danish medical bulletin,
G Nappi, and F Petraglia, and E Martignoni, and F Facchinetti, and G Bono, and A R Genazzani
January 1990, Revue neurologique,
Copied contents to your clipboard!